Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

Yun Wang, Weida Wang, Jingbo Xu, Ji Ma, Hua Wang, Bingyi Wu, Yuanbin Song, Weiran Lv, Lezong Chen, Jun Ma, Tiejun Gong, Yang Liang

Blood (2024) 144 (Supplement 1): 6074.

https://doi.org/10.1182/blood-2024-209055

Published: 2024

Journal Articles

BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models

Jun Ma, Michael P Randall, Ming Lu, Lingjing Chen, Huimin Geng, Aishwarya Kumar, Saloni Malla, Mark Noviski, Ryan Rountree, James L. Rubenstein

Blood (2024) 144 (Supplement 1): 2988.

https://doi.org/10.1182/blood-2024-211266

Published: 2024

Journal Articles

Fatty Acid Metabolism Shapes Immune Function and PI3K Inhibitor Sensitivity in Chronic Lymphocytic Leukemia

Yang Zhang, Jun Ma, Hua Wang, Pan Gao, Xin Wang, Ya Zhang

Blood (2024) 144 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2024-208098

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome Containing Regimen in Patients with Adult Acute Lymphoblastic Leukemia: A Multicenter, Retrospective, Real-World Study

JUN MA, Tiejun Gong, Donglu Zhao, Xiaoyu Zhu, Xiaojing Yan, Junjie Ma, Yun Cai, HongXiang Wang, Mei Hong, Li Liu, Qiang Song, Xin Wang

Blood (2023) 142 (Supplement 1): 5897.

https://doi.org/10.1182/blood-2023-187864

Published: 2023

Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood (2023) 142 (Supplement 1): 4458.

https://doi.org/10.1182/blood-2023-181385

Published: 2023

Journal Articles

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

Jun Ma, Li Zhiming, Wei Xu, Yao Liu, Weili Zhao, Zhihua Yao, Kaiyang Ding, Yudan Wu, Hong Liu, Wenyu Li, Yirong Jiang, Li'e Lin, Zhigang Peng, Zhimin Zhai

Blood (2022) 140 (Supplement 1): 12130–12132.

https://doi.org/10.1182/blood-2022-166137

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Jun Ma, Yuqin Song, Yan Xie, Hui-Lai Zhang, Yuerong Shuang, Zhigang Peng, Li Fei, Yunhong Huang, Weili Zhao, Wenrong Huang, Yali Pan, Mingying Liu, Feiwu Ran, Hui Feng, Sheng Yao, Patricia Keegan, Jianjun Zou, Jun Zhu

Blood (2022) 140 (Supplement 1): 3716–3717.

https://doi.org/10.1182/blood-2022-157497

Published: 2022

Journal Articles

Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

Hui-qiang Huang, Zengjun Li, Gang Cheng, Gao Yan, Zhihua Yao, Guifang Zhang, Xiaoguang Wang, Zhengxiang Han, Yong Chen, Haijiao Yan, Weie Zheng, Jun Yan, Yulan Gu, Zhangxia Ren, Rusen Zhao, Ningling Zhang, Jun Ma

Blood (2021) 138 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2021-149884

Published: 2021

Journal Articles

Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies

Daniel W Robbins, Mark Noviski, Ryan Rountree, May Tan, Nivetha Brathaban, Timothy Ingallinera, Dane E Karr, Aileen Kelly, Zef Konst, Jun Ma, Austin Tenn-McClellan, Jenny McKinnell, Luz Perez, Cristiana Guiducci, Gwenn Hansen, Arthur Sands

Blood (2021) 138 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2021-147473

Published: 2021

Journal Articles

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Zhijian Cao, MD, Jun Ma, MD PhD

Blood (2019) 134 (Supplement_1): 5478.

https://doi.org/10.1182/blood-2019-126686

Published: 2019

Journal Articles

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Tristan Knight, MD, Xinan Qiao, BS, Jun Ma, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Kathryn White, Hai Lin, MD, Yue Wang, Jeffrey W. Taub, MD, Yubin Ge, PhD

Blood (2019) 134 (Supplement_1): 1262.

https://doi.org/10.1182/blood-2019-123793

Published: 2019

Journal Articles

Efficacy and Safety of Low-Dose Decitabine in Low- or Intermediate 1-Risk MDS

Zhijian Cao, MD, Jun Ma

Blood (2018) 132 (Supplement 1): 4377.

https://doi.org/10.1182/blood-2018-99-118683

Published: 2018

Journal Articles

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Yongwei Su, Xinyu Li, Jianyun Zhao, Jun Ma, Shuang Liu, Holly Edwards, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 1255.

https://doi.org/10.1182/blood.V130.Suppl_1.1255.1255

Published: 2017

Journal Articles

Oral Arsenic Plus Retinoic Acid Versus Intravenous Arsenic Plus Retinoic Acid for Non-High Risk Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trials

Honghu Zhu, Depei Wu, MD, Xi Zhang, MD PhD, Lin LIU, Jun Ma, Zonghong Shao, MD, Hanyun Ren, MDPhD, Jianda Hu, Prof MDPhD, Kailin Xu, MD, PhD, Jing-Wen Wang, Yongping Song, Mei-Yun Fang, Xiao-Jun Huang, MD

Blood (2017) 130 (Supplement 1): 641.

https://doi.org/10.1182/blood.V130.Suppl_1.641.641

Published: 2017

Journal Articles

A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy

Zhangyuan Kong, Ping Qin, Shan Xiao, Hai Zhou, Hong Li, Renchi Yang, Xiaofan Liu, Jianmin Luo, Zhichun Li, Guochao Ji, Zhongguang Cui, Yusheng Bai, Yuxia Wu, Linlin Shao, Jun Peng, Jun Ma, Ming Hou

Blood (2017) 130 (9): 1097–1103.

https://doi.org/10.1182/blood-2017-01-761262

Published: 2017

Journal Articles

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Xinyu Li, Jun Ma, Yongwei Su, Jianyun Zhao, Holly Edwards, Yue Wang, Jay Yang, MD, Jeffrey W Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2016) 128 (22): 1571.

https://doi.org/10.1182/blood.V128.22.1571.1571

Published: 2016

Journal Articles

Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study

Qian Jiang, MD, Jianda Hu, MD PhD, Fang Zheng, Xin Du, Li Meng, Depei Wu, MD PhD, Bingcheng Liu, Zhuogang Liu, Jun Ma, MD, Ming Hou, MD PhD, Sixuan Qian, Qingshu Zeng, Yu Hu, Xiaojun Huang

Blood (2016) 128 (22): 5439.

https://doi.org/10.1182/blood.V128.22.5439.5439

Published: 2016

NARROW

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Mitoxantrone Hydrochloride Liposome Combined with Cytarabine As Induction Therapy for Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia

BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models

Fatty Acid Metabolism Shapes Immune Function and PI3K Inhibitor Sensitivity in Chronic Lymphocytic Leukemia

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Mitoxantrone Hydrochloride Liposome Containing Regimen in Patients with Adult Acute Lymphoblastic Leukemia: A Multicenter, Retrospective, Real-World Study

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies

Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Efficacy and Safety of Low-Dose Decitabine in Low- or Intermediate 1-Risk MDS

Targeting PI3K, mTOR, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Oral Arsenic Plus Retinoic Acid Versus Intravenous Arsenic Plus Retinoic Acid for Non-High Risk Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trials

A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy

Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo

Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only